Vadim Koshkin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, gives an update on the Phase II trial (NCT02451423) evaluating escalating doses of neoadjuvant atezolizumab for patients with muscle-invasive bladder cancer (MIBC) prior to radical cystectomy. 20 patients with MIBC participated in the trial. Among evaluable patients, the 2-year relapse-free survival (RFS) was 64% and overall survival (OS) was 75%. This interview took place during the 2021 Genitourinary Cancers Symposium.